Rustgi Vinod K
Transplant Institute, Georgetown University Medical Center, Fairfax, VA 22031, USA.
Expert Rev Anti Infect Ther. 2005 Dec;3(6):885-92. doi: 10.1586/14787210.3.6.885.
Approximately 50% of treatment-naive hepatitis C patients fail to achieve a sustained virologic response with standard peginterferon and ribavirin therapy. Patients who are infected with genotype 1 have high viral loads and are nonresponders to previous therapy, and are even more difficult to treat, underscoring the need for new therapeutic options. Thymalfasin (thymosin-alpha1), in combination with peginterferon-alpha2a, has demonstrated efficacy among difficult-to-treat patients with hepatitis C. The addition of ribavirin to thymalfasin and peginterferon-alpha2a has also exhibited promising results among patients who have genotype 1 hepatitis C, high viral loads and are nonresponders to previous therapy.
大约50%未经治疗的丙型肝炎患者采用标准聚乙二醇干扰素和利巴韦林治疗未能实现持续病毒学应答。感染基因1型的患者病毒载量高，对既往治疗无反应，治疗起来更加困难，这凸显了对新治疗方案的需求。胸腺法新（胸腺肽α1）联合聚乙二醇干扰素α2a已在难治性丙型肝炎患者中显示出疗效。在胸腺法新和聚乙二醇干扰素α2a基础上加用利巴韦林，在基因1型丙型肝炎、病毒载量高且对既往治疗无反应的患者中也显示出了有前景的结果。
